Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.47 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | GALR2 | O43603 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7790042 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTALDH1A1KMT2AHPGD | |
| SCHEMBL7723906 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPTALDH1A1KMT2AHPGD | |
| SCHEMBL426382 | 0.85 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPTALDH1A1KMT2AHPGD | |
| SCHEMBL6750268 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2MAPTALDH1A1KMT2AHPGD | |
| SCHEMBL5925545 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2MAPTALDH1A1KMT2AHPGD | |
| SCHEMBL615906 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTALDH1A1KMT2ATDP1 | |
| SCHEMBL2721981 | 0.83 | ALDH1A1 (0.49) | SMN1; SMN2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL429791 | 0.83 | SMN1; SMN2 (0.61) | SMN1; SMN2MAPTALDH1A1KMT2AHPGD | |
| SCHEMBL8490992 | 0.82 | TDP1 (0.70) | SMN1; SMN2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL25837923 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPTALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105418431-A | Synthesis method of 2-chloro-6-bromo-p-nitrobenzoic acid | DING YUQIN | 2016-03-23 | — | — | CN | claimed |
| EP-4647127-A2 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-3743070-B1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250115577-A1 | BCL-2 Inhibitors | Eil Therapeutics, Inc. | 2025-04-10 | — | — | US | disclosed |
| EP-4457223-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-114040911-B | As NAV1.8 2, 3-Dihydro-quinazoline Compounds as inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118451070-A | BCL-2 inhibitors | 伊尔治疗学股份有限公司 | 2024-08-06 | — | — | CN | disclosed |
| CN-117820226-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117624045-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117603138-A | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2020261114-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
| EP-3743070-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| CN-111757735-A | Compounds for the treatment of kinase-dependent disorders | 埃克塞里艾克西斯公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2019148044-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| CN-105418431-A | Synthesis method of 2-chloro-6-bromo-p-nitrobenzoic acid | DING YUQIN | 2016-03-23 | — | — | CN | disclosed |
| WO-2015049629-A1 | IMIDAZOQUINOLINE COMPOUNDS AS BROMODOMAIN INHIBITORS | Piramal Enterprises Limited (IN) | 2015-04-09 | — | — | WO | disclosed |
| US-6251917-B1 | Benzamidoaldehydes and their use as cysteine protease inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-26 | — | — | US | disclosed |
| CN-1295558-A | Novel local anesthetic compounds and uses | ADVANCED MEDICINE INC (US) | 2001-05-16 | — | — | CN | disclosed |
| US-5475132-A | Fungicide intermediates | RHONE-POULENC AGROCHIMIE (FR) | 1995-12-12 | — | — | US | disclosed |
| US-5342835-A | Antifungal agents based on amides containing a phenyl group | RHONE-POULENC AGROCHIMIE (FR) | 1994-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115577-A1 | BCL-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | SMN1; SMN2 1340/4885MAPT 3121/4885ALDH1A1 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.